Pharmacoeconomics and Health Technology Assessment - GAF287

• Title: Pharmacoeconomics and Health Technology Assessment
• Guaranteed by: Department of Social and Clinical Pharmacy (16-16220)
• Faculty: Faculty of Pharmacy in Hradec Králové
• Actual: from 2024
• Semester: winter
• Points: 0
• E-Credits: 2
• Examination process: winter s.:oral
• Hours per week, examination: winter s.:0/14, Ex [HS]
• Capacity: unknown / unlimited (unknown)
• Min. number of students: 5
• 4EU+: no
• Virtual mobility / capacity: no
• State of the course: taught
• Language: English
• Teaching methods: full-time
• Note: course can be enrolled in outside the study plan; enabled for web enrollment
• Guarantor: PharmDr. Jiří Klimeš, Ph.D.

Annotation

English

The aim is to make students familiar with the complex evaluation of health interventions (technologies), namely drugs, concerning their relative/comparative efficacy, safety and cost-effectiveness. These aspects are integrated within HTA (Health Technology Assessment), which represents an important objective tool for fair and balanced definition and understanding of the added value of drugs (and health technologies in general). In developed countries across the globe, HTA systems are commonly applied as a part of regulatory and decision-making processes, including pricing and reimbursement of health technologies and/or their inclusion and positioning in national formularies, guidelines, or therapeutic standards. In the Czech Republic and other European countries the environment in terms of HTA development is under cultivation. The demand for knowledge and methods in this healthcare areas has been growing both at the site of public authorities (e.g. ministry of health, drug agency), 3rd party payers i.e. insurance funds, healthcare providers and healthcare (pharmaceutical, medical devices) industry. The topics presented and discussed will focus on current HTA practices and they also follow-up on particular chapters taught in social pharmacy subject.

Last update: Klimeš Jiří, PharmDr., Ph.D. (29.09.2022)

Czech

Cílem tohoto předmětu je seznámit studenty s problematikou komplexního posouzení zdravotních intervencí (technologií), především léků, a to s ohledem na jejich účinnost, relativní/komparativní účinnost a nákladovou efektivitu. Všechny tyto aspekty integruje systém HTA (Health technology assessment), který je nezastupitelný ve smyslu správného definování a pochopení hodnoty léčivých přípravků a zdravotních intervencí obecně. Ve vyspělých zemích (nejen) Evropy je systém HTA běžně aplikován jak v regulačních procesech (stanovení výše cen/úhrad/bodových hodnot různým typům intervencí včetně léčiv) tak v rozhodovacích procesech při výběru správné terapie (účinné, bezpečné a nákladově efektivní) pro konkrétní pacienty v praxi. V České republice dochází ke kultivaci prostředí a zavádění principů HTA, přičemž přirozeně roste poptávka po znalostech právě z této oblasti, a to jak na straně státních autorit (Ministerstvo zdravotnictví, Státní ústav pro kontrolu léčiv), zdravotních pojišťoven, zdravotnických zařízení (především velkých nemocnic), tak i farmaceutického průmyslu (uvádění léčiv na trh, oblast klinického výzkumu a vývoje). Probíraná problematika se zaměřením na aktuální praxi navazuje na vybrané kapitoly z předmětu sociální farmacie.

Last update: Klimeš Jiří, PharmDr., Ph.D. (29.09.2022)

Course completion requirements

Credit = team (2 – 3 students) work presentation

Last update: Klimeš Jiří, PharmDr., Ph.D. (29.09.2022)

Literature

Recommended:

• Drummond, Michael. Methods for the economic evaluation of health care programmes. Oxford ; New York: Oxford University Press, 2005, 379 s. ISBN 0-19-852945-7.
• Kobelt G. Health Economics: an Introduction to Economic Evaluation. 3rd Edition, London, Office of H
• International Society for Pharmacoeconomics and Outcomes Research

Last update: prepocet_literatura.php (19.09.2024)

Teaching methods

Interactive seminar

 

Last update: Klimeš Jiří, PharmDr., Ph.D. (29.09.2022)

Requirements to the exam

Conditions for successful completion of the course:

·         Credit: 100% participation in seminars

·         Exam: group project + colloquium

 

Tompics for the final colloquium:

·         Financing and organization of health care taking into account pharmacotherapy

·         Characteristics of HTA (health technology assessment), partial aspects

·         basic concepts from health economics and pharmacoeconomics

·         Basic types of HE analysis

·         regulatory processes: registration vs. determining the reimbursement of medicines

·         basic concepts of evidence-based medicine and interpretation of medical evidence (clinical studies, meta-analyses, indirect comparisons)

·         sources of expert information on medicines

·         hierarchy of expert evidence

·         different types of clinical outcomes, surrogate markers, QALY

·         pharmacoeconomic modeling, reasons, practical procedures

·         integration of clinical, economic and other aspects in a comprehensive HTA report

Last update: Klimeš Jiří, PharmDr., Ph.D. (29.09.2022)

Syllabus

·         Funding and organization of health care, focus on pharmaceuticals ·         HTA (Health Technology Assessment) characteristics, definition ·         Health economics and pharmacoeconomics ·         Regulatory processes: marketing authorization vs. reimbursement and patient access ·         Clinical evidence interpretation (clinical studies, meta-analyses, indirect comparisons) ·         Evidence hierarchy, sources of evidence-base medicine ·         Range of clinical outcomes: from surrogates to QALY (Quality-Adjusted Life-Year)  ·         Pharmacoeconomic modelling: reasons, approaches, methods ·         Integrations of various evidence types (clinical, economic) in complex HTA report ·         In practice lessons the abovementioned topics are discussed and exercised using real-world model examples in pharmacotherapy of osteoporosis and diabetes.

Last update: Klimeš Jiří, PharmDr., Ph.D. (29.09.2022)

Learning outcomes

  

Last update: Navrátilová Lucie, Ing. (24.02.2025)